Business · 01/06/2007Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for GEM 21S GROWTH-FACTOR ENHANCED MATRIX Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the review period for a patent extension application for the medical device GEM 21S GROWTH-FACTOR ENHANCED MATRIX, as required by law.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →